| Project/Area Number |
15K09701
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Toho University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
舘野 昭彦 東邦大学, 医学部, 教授 (10138993)
|
|---|
| Research Collaborator |
INUI Ayano
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | B型肝炎ウイルス / 母子感染 / ワクチン / HBIG / S抗原 / 変異株 / minor clone / 予防不成功 / 遺伝子変異 / 感染予防 / B型肝炎 / 変異ウイルス |
|---|
| Outline of Final Research Achievements |
The frequency of the G145R mutant as a minor as well as major strain was approximately 25% in children who were infected due to immunoprophylaxis failure. HBeAg positivity and high viremia were closely related to the detection of the G145R mutant as a minor population in patients without a history of HB vaccinations, HBIG, or antiviral treatment. Although the G145R mutant as a minor population was detected in pregnant women who were HBeAg-positive and had a high viral load, none of the infants born to the mothers infected with the G145R mutation showed breakthrough infection. Thus, the pre-existence of the G145R mutation as a minor population in mothers does not always cause immunoprophylaixs failure after birth. However, treatment with nucleotide analogues for HBV carrier pregnant women, based on an HBeAg-positive status and the level of HBV DNA, should be encouraged to reduce the risk of breakthrough infection.
|
